Companies
Medik8
produces Liquid Peptides, a 30%-concentration complex of ten peptides including copper peptides targeting initial signs of aging, alongside Liquid Peptides Advanced MP using GF MiniProteins and Dual MiniProteins for deeper delivery.
- Country
- United Kingdom
copper-peptide-serum
eu
Coverage
| US | |
|---|---|
| specialty-fine-chem | ✓ |
Regulatorsfdareach
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Majority stake acquired by L'Oréal in June 2025; Inflexion retains minority stake | beautyindependent.com · inflexion.com · loreal.com · vogue.com |
| Production site | Innovation Centre near Aylesbury, Buckinghamshire (UK) | impact-reporting.com · inflexion.com · medik8.com |
| Certification | ISO 22716, ISO 9001, and B Corp certified | impact-reporting.com · medik8.com |
| Headcount | 284 employees (as of 2025) | open.endole.co.uk · pomanda.com |
| Revenue | £135.68 million (for the period ending December 2025) | open.endole.co.uk · pomanda.com · vogue.com |
| Regulatory approval | Transaction pending regulatory approvals as of June 2025 | loreal.com |
Independent sources: beautyindependent.com · impact-reporting.com · inflexion.com · loreal.com · open.endole.co.uk · pomanda.com · vogue.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bioactive cosmetic peptides & growth factors | specialty-fine-chem | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.